CytRx Publishes INNO-206 Findings In Multiple Myeloma In Cancer Research - RTT News

(RTTNews) - CytRx Corp. (CYTR: News ) announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the ...

CytRx Corporation : CytRx Announces the Publication of INNO-206 Findings in Multiple Myeloma in Clinical Cancer Research - 4-traders (press release)

"We found that, in our mouse models of human myelomas, INNO-206 alone produced marked anti-multiple myeloma effects at a dose at which doxorubicin alone was extremely toxic, and the combination of INNO-206 and bortezomib produced increased anti-multiple ...

Three Biotechs to Watch Before, During, and After This Year's ASCO: CYCC, CYTR, OPTR - Small Cap Network

And the prod? CYTR has developed a doxorubicin conjugate (INNO-206) that has showed anti-multiple myeloma effects, as well as enhanced the anti-tumor effects of bortezomib. The efficacy of the combination isn't new; the results of Phase 1/2 trial were ...

ZYTIGA® (abiraterone acetate) Data to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting - Stockhouse

About VELCADE ® (bortezomib) [3] VELCADE ® (bortezomib) is a first-in-class proteasome inhibitor approved in the EU for use in combination with melphalan and prednisone in previously untreated patients with multiple myeloma (i.e. the front line setting ...

Onyx Pharmaceuticals Announces Data Presentations at 48th American Society of Clinical Oncology Annual Meeting - Yahoo Finance

The head-to-head trial will evaluate the combination of Kyprolis and low-dose dexamethasone vs. the combination of bortezomib and low-dose dexamethasone.  A Phase 1/2 study being conducted by Onyx's partner Ono Pharmaceutical Co., Ltd is ...

Aeterna Zentaris Regains North American Rights for Perifosine from Keryx - TradersHuddle.com

Paul Richardson, MD, Clinical Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute commented, "On behalf of my colleagues involved worldwide in the ongoing pivotal trial comparing bortezomib and dexamethasone alone to the ...